22 de febrero de 2020
 
- Comunicado -

BYETTA(R) es aceptado para uso en pacientes antes de comenzar con la terapia de insulina (y 2)

Actualizado 10/07/2007 23:02:50 CET


REFERENCIAS
(1) www.scottishmedicines.org.uk
(2) Diabetes UK: State of the Nations 2006. January 2007
(3) Swedish Pharmaceutical Benefits Board (LFN) www.lfn.se
(4) The European Public Assessment Report for Byetta. Available at
http://www.emea.europa.eu/humandocs/Humans/EPAR/byetta/byett....
Accessed July 5, 2007.
(5) Barnett AH, Trautmann M, Burger J, Johns D, Kim D, Brodows R, Festa
A, Roberts A. A comparison of exenatide and insulin glargine in
patients using a single oral antidiabetic agent. Data disclosure at
the 42nd annual meeting of the European Association of the Study of
Diabetes. September 16, 2006.
(6) Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG.
Exenatide versus insulin glargine in patients with suboptimally
controlled type 2 diabetes: A randomized trial. Annals of Internal
Medicine 2005; 143(8):559-69.
(7) Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows B,
Trautmann M. A comparison of twice-daily exenatide and biphasic
insulin aspart in patients with type 2 diabetes who were
suboptimally controlled with sulfonylurea and metformin: A
noninferiority study. Diabetologia 2007; 50:259-267
(8) Trautmann ME., Burger J., Johns D., Brodows R., Okerson T., Roberts
A., and Barnett A. Less hypoglycemia with exenatide versus insulin
glargine, despite similar HbA1c improvement, in patients with T2DM
adjunctively treated with metformin. Data disclosure at the 67th
Scientific Sessions of the American Diabetes Association, June 24,
2007, Abstract # 0172-OR.
(9) The International Diabetes Federation Diabetes Atlas. Available at:
http://www.idf.org/home/index.cfm?unode=3B96906B-C026-2FD3-8....
Accessed June 14, 2007.
(10) The International Diabetes Federation, Prevalence / All diabetes.
Available at http://www.eatlas.idf.org/Prevalence/All_diabetes/.
(11) Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet,
sulfonylurea, metformin, or insulin in patients with type 2 diabetes
mellitus: progressive requirement for multiple therapies (UKPDS 49).
JAMA 1999; 281(21):2005-2012.
(12) The International Diabetes Federation, Complications. Available at
http://www.eatlas.idf.org/Complications/
(13) The International Diabetes Federation, Diabetes Atlas, Second
edition. The Economic Impact of Diabetes. 2003:186.

Derin Denham de Eli Lilly and Company, +1-317-277-6749 oficina, o +1-317-370-1435 móvil. Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO , PRN Photo Desk, photodesk@prnewswire.com

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación

Lo más leído

  1. 1

    Científicos finalmente confirman una teoría mecánica de 50 años

  2. 2

    Ya es oficial: habrá reunión de Friends con todos sus protagonistas en HBO

  3. 3

    El Sombrero invierte la teoría galáctica convencional

  4. 4

    Italia eleva a 17 el número de casos confirmados de coronavirus

  5. 5

    González dice que se le cayeron "los palos del sombrajo" al intentar verse representado en la investidura de Sánchez